Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Finished Goods (2022 - 2026)

Neuroone Medical Technologies filings provide 5 years of Finished Goods readings, the most recent being $488561.0 for Q1 2026.

  • On a quarterly basis, Finished Goods fell 10.47% to $488561.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $488561.0, a 10.47% decrease, with the full-year FY2025 number at $1.2 million, down 21.75% from a year prior.
  • Finished Goods hit $488561.0 in Q1 2026 for Neuroone Medical Technologies, down from $518209.0 in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $1.6 million in Q3 2024 to a low of $73968.0 in Q3 2022.
  • Median Finished Goods over the past 5 years was $545671.0 (2025), compared with a mean of $648815.5.
  • Biggest five-year swings in Finished Goods: soared 768.35% in 2024 and later plummeted 41.11% in 2025.
  • Neuroone Medical Technologies' Finished Goods stood at $73968.0 in 2022, then surged by 143.47% to $180092.0 in 2023, then soared by 388.62% to $879966.0 in 2024, then plummeted by 41.11% to $518209.0 in 2025, then dropped by 5.72% to $488561.0 in 2026.
  • The last three reported values for Finished Goods were $488561.0 (Q1 2026), $518209.0 (Q4 2025), and $1.2 million (Q3 2025) per Business Quant data.